CurrentEmblemHealthPolicy N/A

Vectibix (panitumumab) — Coverage Criteria for Colorectal Cancer

Defines accepted indications, documentation, and coverage criteria for panitumumab (Vectibix) in cancer treatment for EmblemHealth members; applies to providers submitting medication requests processed by Evolent. Affects all lines of business listed in the policy.

Policy Summary

PayerEmblemHealth

PolicyVectibix (panitumumab) — Coverage Criteria for Colorectal Cancer

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization (HCPCS J9303) and document KRAS/NRAS/BRAF testing results to support coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

J9303HCPCS code for panitumumab

6 mg/kgsingle dose maximum

RAS/BRAF WTrequired biomarker status

Approved lineslines supported

Multiplelines of business

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Covered Indications - Colorectal Cancer

Covered when ANY of the following clinical scenarios are met for colorectal cancer:

Colorectal indications

Primary setting: advanced/metastatic colorectal cancer with KRAS/NRAS/BRAF wild-type: Member has KRAS/NRAS/BRAF wild-type advanced or metastatic colorectal cancer
Used in combination with FOLFOX or FOLFIRI; capecitabine (Xeloda) may substitute for 5-FU in 5-FU–based regimens.
Subsequent therapy: single agent or with irinotecan: Use as a single agent or in combination with irinotecan for subsequent therapy following prior chemotherapy for metastatic diseaseprior exposure to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy when applicable
BRAF V600E-mutant setting with encorafenib: Vectibix may be used as subsequent therapy in combination with encorafenib for members with unresectable/metastatic disease with BRAF V600E mutationBRAF V600E mutation positive
Coverage regardless of KRAS/NRAS status.
KRAS G12C-mutated setting with sotorasib: Vectibix may be used in combination with sotorasib for adult members with KRAS G12C-mutated metastatic colorectal cancerKRAS G12C mutation confirmed by an FDA-approved test; prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
For use in members who have received prior standard chemotherapy regimens.

Use of Vectibix (panitumumab) is not covered when there is disease progression on panitumumab or when the member has failed cetuximab (Erbitux). Requests will also be excluded if the provider does not document required molecular testing — specifically the presence of KRAS/NRAS/BRAF testing and the results for the indication being requested. In addition, dosing that exceeds the policy single‑dose limit of 6 mg/kg is not allowable for coverage. Documentation gaps in these areas are grounds for denial of the request.

Panitumumab use for indications that are off‑label or investigational is excluded when the supporting evidence is insufficient or not generally accepted by the medical community. Insufficient evidence includes a lack of representation of the patient population or treatment regimen in published studies, study outcomes that are not clinically meaningful (for example, failing to meet commonly accepted thresholds such as a hazard ratio < 0.80 or a survival benefit of at least 3 months for OS or PFS), inadequate study design for the question being asked, reliance on uncontrolled case reports, or reliance on abstracts without a full peer‑reviewed publication. Coverage for off‑label uses requires support from CMS‑recognized compendia or acceptable peer‑reviewed literature that adequately address these criteria.

Regimen / Combination	Notes / Eligibility	Coverage Label
FOLFOX (fluorouracil, leucovorin, and oxaliplatin) in combination with panitumumab
Member must have KRAS/NRAS/BRAF wild-type advanced or metastatic colorectal cancer; capecitabine (Xeloda) may be substituted for 5‑FU in 5‑FU–based regimens.
Covered
FOLFIRI (fluorouracil, leucovorin, and irinotecan) in combination with panitumumab
Member must have KRAS/NRAS/BRAF wild-type advanced or metastatic colorectal cancer; capecitabine may be substituted for 5‑FU in 5‑FU–based regimens.
Covered
Panitumumab as single agent or in combination with irinotecan for subsequent therapy
Use for subsequent therapy following prior chemotherapy for metastatic disease (after prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based regimens as applicable).
Covered
Panitumumab + encorafenib (Braftovi)
For unresectable/metastatic disease with BRAF V600E mutation positive; coverage regardless of KRAS/NRAS status.
Covered
Panitumumab + sotorasib (Lumakras)
For adult members with KRAS G12C‑mutated metastatic colorectal cancer (FDA‑approved test) who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy.
Covered

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for panitumumab (HCPCS J9303). Continuation requests may be exempt from prior authorization when all of the following are met: the member has not experienced disease progression on panitumumab; the medication was used within the last year without a lapse of more than 30 days of having an active authorization; and no additional medications are being added to the continuation request.

Affected code: HCPCS J9303 (panitumumab)
Continuation exemption conditions: no progression on drug; prior use within last year without >30 day lapse; no new agents added

Step Therapy

Regimen and Sequence Expectations

Panitumumab (Vectibix) should be used in specified regimens and sequences for colorectal cancer: in members with KRAS/NRAS/BRAF wild-type advanced or metastatic colorectal cancer, panitumumab may be used in combination with FOLFOX or FOLFIRI; or as a single agent or in combination with irinotecan for subsequent therapy following prior chemotherapy for metastatic disease. Capecitabine (Xeloda) may substitute for 5-FU in these 5-FU–based regimens. Panitumumab may also be used as subsequent therapy in combination with encorafenib (Braftovi) for unresectable/metastatic BRAF V600E–mutant disease, and in combination with sotorasib (Lumakras) for KRAS G12C–mutated metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Acceptable combinations: FOLFOX + panitumumab; FOLFIRI + panitumumab
Subsequent therapy: panitumumab alone or with irinotecan following prior chemotherapy
Substitutions: capecitabine may replace 5-FU in 5-FU–based regimens
Biomarker-directed combinations: panitumumab + encorafenib for BRAF V600E mutation; panitumumab + sotorasib for KRAS G12C mutation after prior chemo

Documentation Required

Required Supporting Documentation

Use of panitumumab must be supported by FDA labeling, CMS-recognized compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature. Continuation requests and prior-authorized use must include documentation demonstrating adherence to authorized regimens and biomarker status. Providers should supply clinical notes, prior treatment history, and test results when submitting requests.

Acceptable evidence sources: FDA labeling; CMS-recognized compendia; NCCN or ASCO guidelines; peer-reviewed literature meeting CMS standards
Required documentation: clinical rationale, prior chemotherapy regimen details, treatment dates, and copies of KRAS/NRAS/BRAF (and relevant mutation) test results

Denial Risk

Denial Conditions and Exclusions

Requests will be denied when exclusion criteria are met, including disease progression on panitumumab, prior failure of cetuximab (Erbitux), absence of documented KRAS/NRAS/BRAF testing/results when required, dosing that exceeds the single-dose limit (6 mg/kg), or when the requested use is investigational/off-label without sufficient supporting evidence from accepted sources.

Denial triggers: progression on panitumumab
Denial triggers: prior cetuximab (Erbitux) failure
Denial triggers: missing or absent documentation of KRAS/NRAS/BRAF testing and results for indicated uses
Denial triggers: dosing > single-dose limit of 6 mg/kg
Denial triggers: investigational or off-label indications lacking support from CMS compendia or acceptable peer-reviewed literature

Molecular and Biomarker Requirements

KRAS, NRAS, BRAF — biomarker contexts

Requirement for primary colorectal indicationTumor must be KRAS, NRAS, and BRAF wild-type for use in the primary advanced/metastatic colorectal cancer indication

BRAF V600E contextVectibix may be used with encorafenib for unresectable/metastatic disease with BRAF V600E mutation positive regardless of KRAS/NRAS status

KRAS G12C contextVectibix may be used in combination with sotorasib for KRAS G12C–mutated metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy

KRAS/NRAS/BRAF wild-type — definition & implication

DefinitionKRAS/NRAS/BRAF wild-type = tumor RAS and BRAF gene status indicating absence of activating mutations (required for primary colorectal indication)

Clinical implicationPanitumumab (Vectibix) is indicated for use in advanced/metastatic colorectal cancer when these genes are wild-type; without documented wild-type status use is excluded

Documentation requirementAbsence of documented KRAS/NRAS/BRAF testing and results for the indicated uses is an exclusion trigger

Permitted Lines of Therapy

inv-12: first-line | second-line | subsequent

Line of therapy options

First or any line with chemotherapy: Use in combination with FOLFOX or FOLFIRI in advanced/metastatic colorectal cancer for members with appropriate molecular profile
Capecitabine may substitute for 5-FU in 5-FU–based regimens.
Subsequent therapy (single agent/with irinotecan): As single agent or in combination with irinotecan following prior chemotherapy for metastatic diseaseprior exposure to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy when applicable
Subsequent targeted combinations: Use with encorafenib for BRAF V600E mutant disease; use with sotorasib for KRAS G12C mutant disease after prior standard chemotherapyBRAF V600E mutation positive for encorafenib combination; KRAS G12C mutation confirmed by FDA‑approved test for sotorasib combination
Coverage of encorafenib combination is regardless of KRAS/NRAS status.

Background

Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is used in the management of advanced or metastatic colorectal cancer. Clinical benefit from panitumumab is dependent on tumor molecular profile; the policy requires appropriate RAS/BRAF testing because efficacy is limited to patients with the specified biomarker status (for primary colorectal indications, KRAS/NRAS/BRAF wild‑type). Panitumumab is described for use in combination with chemotherapy backbones such as FOLFOX or FOLFIRI, with capecitabine accepted as a substitute for 5‑FU where applicable, or as a single agent or combined with irinotecan in subsequent lines; it may also be combined with targeted agents in biomarker‑selected settings (for example, encorafenib for BRAF V600E or sotorasib for KRAS G12C in the scenarios defined by the policy).

OpenPayer

Vectibix (panitumumab) — Coverage Criteria for Colorectal Cancer

Coverage Criteria for Vectibix (panitumumab)

Billing and Coding

Provider Requirements and Authorization

Molecular and Biomarker Requirements

Permitted Lines of Therapy

Background

Definitions

Revision History